Cross-sectional study to evaluate perceptions of physical activity in patients with hemophilia A treated with emicizumab. HEMO-ACT STUDY
OBSERVATIONAL STUDY WITH MEDICINES
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Execution start: 23/04/2024
- End of execution: 30/03/2025
- IP: LAURA ENTRENA UREÑA